In brief, these findings collectively demonstrate that B68 inhibits the progression of CRC by inducing cellular senescence and reducing the levels of PD‐L1 in the tumor microenvironment and can exert synergistic antitumor effects when combined with CTLA‐4 antibody therapy, thereby further enhancing the response against cancer. The gene discussed is CTLA4; the disease is colorectal carcinoma.